Recent Updates
Recently added Catalysts
FHTX Positive Sentiment

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

Wednesday, February 28, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Foghorn Therapeutics, a biotech company focused on novel medicines for serious diseases, has announced its participation in Cowen's 44th Annual Health Care Conference scheduled for March 4-6, 2024. The company will present its Gene Traffic Control platform, which targets abnormal gene expression, particularly in oncology. Chief Medical Officer Alfonso Quintas-Cardama will present on March 4, and Foghorn will also engage in one-on-one meetings during the event.
Price reaction · baseline $7.2 (2024-02-27 close) · hit after-hours · clean, no other FHTX news in the window
day 0 close · peak
+8.1%
day 1
+7.4%
day 3
-5.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Foghorn Therapeutics is participating in a major health care conference.
  • The company's innovative Gene Traffic Control platform has transformative potential.
  • The event will provide exposure to investors and stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
5.9%
average across 4 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
FHD-286
Phase 2 · Small Cell Lung Cancer

Full Press Release Details

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen’s 44th Annual Health Care Conference, which is taking place on March 4–6, 2024, at the Boston Marriott Copley Place in Boston, MA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Leukemia panel date and time: Monday, March 4, 12:50 p.m. ET
Foghorn Presenter: Alfonso Quintas-Cardama, Chief Medical Officer
Please find a link to the panel here.
Management will also participate in one-on-one meetings during the conference.
A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of Foghorn’s website, www.foghorntx.com, and will be available for up to 30 days.
About Foghorn Therapeutics
Greg Dearborn, Foghorn Therapeutics Inc. (Investors)
gdearborn@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com
Adam Silverstein, ScientPR (Media)
Peter Kelleher, LifeSci Advisors (Investors)

Frequently Asked Questions

What is Foghorn Therapeutics focusing on?

Foghorn Therapeutics focuses on treating serious diseases through abnormal gene expression.

When is the Cowen Health Care Conference?

The Cowen Health Care Conference is from March 4–6, 2024.

Who will present at the conference?

Alfonso Quintas-Cardama, Chief Medical Officer, will present.

When is the leukemia panel scheduled?

The leukemia panel is on March 4 at 12:50 p.m. ET.

Where can I access the webcast of the panel?

The webcast can be accessed on Foghorn's website under ‘Events & Presentations.’

ShareAdd on Google
Tags: FHTX Viatris Investor Conferences Healthcare Cowen conference Gene Traffic Control oncology biotechnology
Last updated: Feb 28, 2024

Biotech snapshot

Cash runway
$168M liquidity · $6M/mo burn
~28 mo
Minimal dilution risk
Lead asset
FHD-286Phase 2
Small Cell Lung Cancer →

Catalyst track record

+56%
best trade around FHTX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for FHTX.

See every catalyst's timing & PoA →